CRO support for ncats medicinal chemistry for lead optimization.

Ended Awarded Last action

Contract number
75N95019D00030
Awardee
Awarding agency
Task orders
1 $1,000 obligated

Award facts

Opportunity
Combined order value
$1,000 Current and potential, with all options
Last date to order 100% complete
IDV ceiling <1% used
$17,891,012.00
Maximum order
$17,887,012.00
Award type
Multiple award
Who can order
Only the awarding agency
Funding agency
National Center for Advancing Translational Sciences National Institutes of Health, Department of Health and Human Services
Set-aside
No set-aside
Competition
Full and Open Competition · 13 offers Negotiated Proposal / Quote
Pricing
Order Dependent (IDV only)
Legislative mandates

Award details come from SAM.gov/FPDS.

About this IDV

This indefinite delivery contract was awarded by the National Center for Advancing Translational Sciences (NCATS), part of the U.S. Department of Health and Human Services, to Lovelace Biomedical Research Institute, a not-for-profit contract research organization based in Albuquerque, New Mexico. The $17.89 million multiple-award contract, which runs through April 2025, is for contract research organization (CRO) support for NCATS' medicinal chemistry work focused on lead optimization.

Under the contract, Lovelace will provide a range of preclinical research services to support drug and product development, including animal studies, analytical testing, disease model development, and manufacturing. The initial task order, valued at $1,000, was for a kickoff conference call related to the medicinal chemistry work. Lovelace also holds multiple other federal contract IDVs and grants with agencies like the NIH, DoD, and BARDA, leveraging its expertise in areas such as inhalation toxicology, infectious disease modeling, and medical countermeasure testing to advance treatments for various diseases and conditions.

Task orders

Transactions

Action Obligated Date
Terminate for Convenience P00006 · EOI::implementing the presidents department of government efficiency cost efficiency initiative (march 19, 2025)::EOI notice of termination for convenience… $0
Supplemental Agreement for work within scope P00005 $0
Other Administrative Action P00004 $0
Funding Only Action P00003 $4,000
Vendor DUNS or Name Change - Non-Novation P00002 $0
Supplemental Agreement for work within scope P00001 $0
Original award $0

Quick answers

Who was awarded contract 75N95019D00030?

75N95019D00030 was awarded to Lovelace Biomedical Research Institute by National Institute on Drug Abuse (National Institutes of Health) on September 26, 2019.

How much is contract 75N95019D00030 worth?

Orders under 75N95019D00030 have obligated $1,000. 75N95019D00030's own ceiling is $17,891,012. A single order can be worth up to $17,887,012.

How many orders have been placed under contract 75N95019D00030?

1 order has been placed under 75N95019D00030, the latest on September 23, 2019.

Which agency awarded contract 75N95019D00030?

National Institute on Drug Abuse (National Institutes of Health) awarded 75N95019D00030, with funding from National Center for Advancing Translational Sciences (National Institutes of Health).

Who can order from contract 75N95019D00030?

75N95019D00030 is a multiple award indefinite delivery contract. Only the awarding agency can place orders on it.

Is contract 75N95019D00030 part of a contract vehicle?

Yes. 75N95019D00030 is part of CRO Support for NCATS Medicinal Chemistry for Lead Optimization.

Was contract 75N95019D00030 competed?

The extent of competition for 75N95019D00030 was full and open competition. The government received 13 offers.

On GovTribe

See this IDV's full record

  • Every order and transaction
  • The awardee's other awards and teaming partners
  • Similar IDVs and recompete opportunities
  • Ask GovTribe AI about this IDV